A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease
The availability of effective treatments for severe Alzheimer disease (AD) has accentuated the need for brief, simple tools to evaluate treatment response in busy clinical settings for patients with advanced dementia. To develop such a tool, data on 875 patients from 4 double-blind-randomized studie...
Gespeichert in:
| Veröffentlicht in: | Alzheimer disease and associated disorders 2009-10, Vol.23 (4), p.377-383 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 383 |
|---|---|
| container_issue | 4 |
| container_start_page | 377 |
| container_title | Alzheimer disease and associated disorders |
| container_volume | 23 |
| creator | SCHMITT, Frederick A SAXTON, Judith A YIKANG XU MCRAE, Thomas YIJUN SUN RICHARDSON, Sharon HONGLAN LI |
| description | The availability of effective treatments for severe Alzheimer disease (AD) has accentuated the need for brief, simple tools to evaluate treatment response in busy clinical settings for patients with advanced dementia. To develop such a tool, data on 875 patients from 4 double-blind-randomized studies of donepezil in severe AD [Mini-Mental State Examination (MMSE) 0 to 12 inclusive] were pooled and analyzed to identify Severe Impairment Battery (SIB) items, which are sensitive to change over time. Eight of the 51 SIB items were chosen based on effect sizes and relative ease of administration. The resulting SIB-8 was then applied to a validation data set (not used to generate the short form) to characterize its usefulness. The items, Month, Months of Year, Write Name, Sentence, Fluency, Confrontational Naming-Spoon, Using Spoon-Photograph, and Digit Span, were sensitive to change with treatment (P |
| doi_str_mv | 10.1097/WAD.0b013e3181ac9cc1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733604863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733604863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-7f0fbc6ccb204d27520aea212d63290f80a51565ce0d92199671e96b116dcac03</originalsourceid><addsrcrecordid>eNpdkF1rFTEQhoMo9rT6D0RyI15tnUl2k83l2g8tFFqk0juXbHaWE9mPYyZH0F_frT0oeDXw8rwzzCPEG4RTBGc_3Dfnp9ABatJYow8uBHwmNliVpiixMs_FBmqnC9AlHolj5u8AYHUFL8URusqiVXYjvjXyY4o0yKuZc9pPNGeZF9kwE7O8S-Tzn-wL8W6ZmWScZd6SvPU5Pub3MW9l0__0c6BeNuPvLcWJkjyPTJ7plXgx-JHp9WGeiK-XF3dnn4vrm09XZ811EbQ2ubADDF0wIXQKyl7ZSoEnr1D1RisHQw2-Wl-qAkHvFDpnLJIzHaLpgw-gT8T7p727tPzYE-d2ihxoHP1My55bu56BsjZ6JcsnMqSFOdHQ7lKcfPrVIrSPYttVbPu_2LX29nBg303U_ysdTK7AuwPgOfhxSKuRyH85pVSNSjn9AIfWggg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733604863</pqid></control><display><type>article</type><title>A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>SCHMITT, Frederick A ; SAXTON, Judith A ; YIKANG XU ; MCRAE, Thomas ; YIJUN SUN ; RICHARDSON, Sharon ; HONGLAN LI</creator><creatorcontrib>SCHMITT, Frederick A ; SAXTON, Judith A ; YIKANG XU ; MCRAE, Thomas ; YIJUN SUN ; RICHARDSON, Sharon ; HONGLAN LI</creatorcontrib><description>The availability of effective treatments for severe Alzheimer disease (AD) has accentuated the need for brief, simple tools to evaluate treatment response in busy clinical settings for patients with advanced dementia. To develop such a tool, data on 875 patients from 4 double-blind-randomized studies of donepezil in severe AD [Mini-Mental State Examination (MMSE) 0 to 12 inclusive] were pooled and analyzed to identify Severe Impairment Battery (SIB) items, which are sensitive to change over time. Eight of the 51 SIB items were chosen based on effect sizes and relative ease of administration. The resulting SIB-8 was then applied to a validation data set (not used to generate the short form) to characterize its usefulness. The items, Month, Months of Year, Write Name, Sentence, Fluency, Confrontational Naming-Spoon, Using Spoon-Photograph, and Digit Span, were sensitive to change with treatment (P<0.0001) and easy to administer. Baseline SIB-8 scores were correlated with baseline MMSE and full-scale SIB scores, and provided a good distribution of scores in patients at the lower end of the MMSE. The SIB-8 is a brief (< or =3 min) assessment for patients with severe AD that is sensitive to change and able to detect treatment response.</description><identifier>ISSN: 0893-0341</identifier><identifier>EISSN: 1546-4156</identifier><identifier>DOI: 10.1097/WAD.0b013e3181ac9cc1</identifier><identifier>PMID: 19571727</identifier><identifier>CODEN: ADADE2</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - diagnosis ; Alzheimer Disease - drug therapy ; Alzheimer Disease - psychology ; Biological and medical sciences ; Cardiovascular system ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Double-Blind Method ; Female ; Humans ; Indans - therapeutic use ; Male ; Medical sciences ; Neurology ; Neuropsychological Tests - standards ; Pharmacology. Drug treatments ; Piperidines - therapeutic use ; Randomized Controlled Trials as Topic - methods ; Randomized Controlled Trials as Topic - psychology ; Severity of Illness Index ; Treatment Outcome ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Alzheimer disease and associated disorders, 2009-10, Vol.23 (4), p.377-383</ispartof><rights>2015 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-7f0fbc6ccb204d27520aea212d63290f80a51565ce0d92199671e96b116dcac03</citedby><cites>FETCH-LOGICAL-c336t-7f0fbc6ccb204d27520aea212d63290f80a51565ce0d92199671e96b116dcac03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22281229$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19571727$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SCHMITT, Frederick A</creatorcontrib><creatorcontrib>SAXTON, Judith A</creatorcontrib><creatorcontrib>YIKANG XU</creatorcontrib><creatorcontrib>MCRAE, Thomas</creatorcontrib><creatorcontrib>YIJUN SUN</creatorcontrib><creatorcontrib>RICHARDSON, Sharon</creatorcontrib><creatorcontrib>HONGLAN LI</creatorcontrib><title>A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease</title><title>Alzheimer disease and associated disorders</title><addtitle>Alzheimer Dis Assoc Disord</addtitle><description>The availability of effective treatments for severe Alzheimer disease (AD) has accentuated the need for brief, simple tools to evaluate treatment response in busy clinical settings for patients with advanced dementia. To develop such a tool, data on 875 patients from 4 double-blind-randomized studies of donepezil in severe AD [Mini-Mental State Examination (MMSE) 0 to 12 inclusive] were pooled and analyzed to identify Severe Impairment Battery (SIB) items, which are sensitive to change over time. Eight of the 51 SIB items were chosen based on effect sizes and relative ease of administration. The resulting SIB-8 was then applied to a validation data set (not used to generate the short form) to characterize its usefulness. The items, Month, Months of Year, Write Name, Sentence, Fluency, Confrontational Naming-Spoon, Using Spoon-Photograph, and Digit Span, were sensitive to change with treatment (P<0.0001) and easy to administer. Baseline SIB-8 scores were correlated with baseline MMSE and full-scale SIB scores, and provided a good distribution of scores in patients at the lower end of the MMSE. The SIB-8 is a brief (< or =3 min) assessment for patients with severe AD that is sensitive to change and able to detect treatment response.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - psychology</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Indans - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Neuropsychological Tests - standards</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - therapeutic use</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Randomized Controlled Trials as Topic - psychology</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0893-0341</issn><issn>1546-4156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF1rFTEQhoMo9rT6D0RyI15tnUl2k83l2g8tFFqk0juXbHaWE9mPYyZH0F_frT0oeDXw8rwzzCPEG4RTBGc_3Dfnp9ABatJYow8uBHwmNliVpiixMs_FBmqnC9AlHolj5u8AYHUFL8URusqiVXYjvjXyY4o0yKuZc9pPNGeZF9kwE7O8S-Tzn-wL8W6ZmWScZd6SvPU5Pub3MW9l0__0c6BeNuPvLcWJkjyPTJ7plXgx-JHp9WGeiK-XF3dnn4vrm09XZ811EbQ2ubADDF0wIXQKyl7ZSoEnr1D1RisHQw2-Wl-qAkHvFDpnLJIzHaLpgw-gT8T7p727tPzYE-d2ihxoHP1My55bu56BsjZ6JcsnMqSFOdHQ7lKcfPrVIrSPYttVbPu_2LX29nBg303U_ysdTK7AuwPgOfhxSKuRyH85pVSNSjn9AIfWggg</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>SCHMITT, Frederick A</creator><creator>SAXTON, Judith A</creator><creator>YIKANG XU</creator><creator>MCRAE, Thomas</creator><creator>YIJUN SUN</creator><creator>RICHARDSON, Sharon</creator><creator>HONGLAN LI</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091001</creationdate><title>A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease</title><author>SCHMITT, Frederick A ; SAXTON, Judith A ; YIKANG XU ; MCRAE, Thomas ; YIJUN SUN ; RICHARDSON, Sharon ; HONGLAN LI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-7f0fbc6ccb204d27520aea212d63290f80a51565ce0d92199671e96b116dcac03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - psychology</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Indans - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Neuropsychological Tests - standards</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - therapeutic use</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Randomized Controlled Trials as Topic - psychology</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>online_resources</toplevel><creatorcontrib>SCHMITT, Frederick A</creatorcontrib><creatorcontrib>SAXTON, Judith A</creatorcontrib><creatorcontrib>YIKANG XU</creatorcontrib><creatorcontrib>MCRAE, Thomas</creatorcontrib><creatorcontrib>YIJUN SUN</creatorcontrib><creatorcontrib>RICHARDSON, Sharon</creatorcontrib><creatorcontrib>HONGLAN LI</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alzheimer disease and associated disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SCHMITT, Frederick A</au><au>SAXTON, Judith A</au><au>YIKANG XU</au><au>MCRAE, Thomas</au><au>YIJUN SUN</au><au>RICHARDSON, Sharon</au><au>HONGLAN LI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease</atitle><jtitle>Alzheimer disease and associated disorders</jtitle><addtitle>Alzheimer Dis Assoc Disord</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>23</volume><issue>4</issue><spage>377</spage><epage>383</epage><pages>377-383</pages><issn>0893-0341</issn><eissn>1546-4156</eissn><coden>ADADE2</coden><abstract>The availability of effective treatments for severe Alzheimer disease (AD) has accentuated the need for brief, simple tools to evaluate treatment response in busy clinical settings for patients with advanced dementia. To develop such a tool, data on 875 patients from 4 double-blind-randomized studies of donepezil in severe AD [Mini-Mental State Examination (MMSE) 0 to 12 inclusive] were pooled and analyzed to identify Severe Impairment Battery (SIB) items, which are sensitive to change over time. Eight of the 51 SIB items were chosen based on effect sizes and relative ease of administration. The resulting SIB-8 was then applied to a validation data set (not used to generate the short form) to characterize its usefulness. The items, Month, Months of Year, Write Name, Sentence, Fluency, Confrontational Naming-Spoon, Using Spoon-Photograph, and Digit Span, were sensitive to change with treatment (P<0.0001) and easy to administer. Baseline SIB-8 scores were correlated with baseline MMSE and full-scale SIB scores, and provided a good distribution of scores in patients at the lower end of the MMSE. The SIB-8 is a brief (< or =3 min) assessment for patients with severe AD that is sensitive to change and able to detect treatment response.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>19571727</pmid><doi>10.1097/WAD.0b013e3181ac9cc1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-0341 |
| ispartof | Alzheimer disease and associated disorders, 2009-10, Vol.23 (4), p.377-383 |
| issn | 0893-0341 1546-4156 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733604863 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Aged, 80 and over Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Alzheimer Disease - psychology Biological and medical sciences Cardiovascular system Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Double-Blind Method Female Humans Indans - therapeutic use Male Medical sciences Neurology Neuropsychological Tests - standards Pharmacology. Drug treatments Piperidines - therapeutic use Randomized Controlled Trials as Topic - methods Randomized Controlled Trials as Topic - psychology Severity of Illness Index Treatment Outcome Vasodilator agents. Cerebral vasodilators |
| title | A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A51%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Brief%20Instrument%20to%20Assess%20Treatment%20Response%20in%20the%20Patient%20With%20Advanced%20Alzheimer%20Disease&rft.jtitle=Alzheimer%20disease%20and%20associated%20disorders&rft.au=SCHMITT,%20Frederick%20A&rft.date=2009-10-01&rft.volume=23&rft.issue=4&rft.spage=377&rft.epage=383&rft.pages=377-383&rft.issn=0893-0341&rft.eissn=1546-4156&rft.coden=ADADE2&rft_id=info:doi/10.1097/WAD.0b013e3181ac9cc1&rft_dat=%3Cproquest_cross%3E733604863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733604863&rft_id=info:pmid/19571727&rfr_iscdi=true |